Benn Diana E, Robinson Bruce G
Cancer Genetics Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards NSW 2065, Australia.
Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):435-50. doi: 10.1016/j.beem.2006.07.005.
Advances in the knowledge of the genetics of phaeochromocytoma have broadened our understanding about the mechanisms of tumorigenesis. Formerly it was believed that 10% of phaeochromocytomas were associated with familial cancer syndromes, but it is now recognised that up to 30% of these tumours may be familial. In particular, attention has been focused on those patients with apparently sporadic presentations where 12-24% of patients have been shown to carry germline mutations indicating hereditary disease. Consideration of genetic testing is now recommended for all apparently sporadic cases and, following the identification of a mutation-positive carrier, the offering of genetic testing to first degree relatives. There is a need for lifelong follow up of affected individuals and asymptomatic mutation-positive carriers, but validation of screening protocols has yet to be determined.
嗜铬细胞瘤遗传学知识的进展拓宽了我们对肿瘤发生机制的理解。以前认为10%的嗜铬细胞瘤与家族性癌症综合征有关,但现在认识到这些肿瘤中高达30%可能是家族性的。特别是,注意力集中在那些表现为散发性的患者身上,其中12 - 24%的患者已被证明携带表明遗传性疾病的种系突变。现在建议对所有明显散发性病例进行基因检测,在确定突变阳性携带者后,为其一级亲属提供基因检测。需要对受影响个体和无症状突变阳性携带者进行终身随访,但筛查方案的验证尚未确定。